MedTrace Logo

Phase I Study of HS-20108 in Participants With Advanced Solid Tumors

NCT06936735 · Status: NOT_YET_RECRUITING · Phase: PHASE1 · Type: INTERVENTIONAL · Enrollment: 502

Last updated 2025-04-20

No results posted yet for this study

Summary

This is a Phase I clinical study of HS-20108. The purpose of this study is to evaluate the safety, tolerability, PK and efficacy of intravenous HS-20108 in patients with advanced solid tumors.

Conditions

  • Advanced Solid Tumor

Interventions

DRUG

HS-20108 Monotherapy

Intravenous (IV) Infusion

Sponsors & Collaborators

  • Hansoh BioMedical R&D Company

    lead INDUSTRY

Principal Investigators

  • Ying Cheng, BMed · Jilin Provincial Tumor Hospital

Study Design

Allocation
NON_RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
SEQUENTIAL

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2025-04-17
Primary Completion
2027-10-28
Completion
2027-11-27

Countries

  • China

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT06936735 on ClinicalTrials.gov